entinostat + anastrozole
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor-negative Breast Cancer
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Trial Timeline
Oct 1, 2010 → May 1, 2017
NCT ID
NCT01234532About entinostat + anastrozole
entinostat + anastrozole is a phase 2 stage product being developed by Syndax Pharmaceuticals for Estrogen Receptor-negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01234532. Target conditions include Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234532 | Phase 2 | Terminated |
Competing Products
20 competing products in Estrogen Receptor-negative Breast Cancer